ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Megestrol Acetate

Also written as “Nano-crystalline Megestrol Acetate Oral Suspension”, “Megestrol acetate concentrated suspension 125 mg/mL” and “Megestrol acetate”.

Its studies are mostly in Anorexia · Cachexia · Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis, led by 6 companies.

Drug pageMegestrol Acetate: every studyMany companies study it; this page follows only the 18 they lead. All 66 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 15, 202518 company-led studies, 7 open or runningNext primary completion: Dec 31, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical77 open or runningphase 4since Nov 15, 2025Dec 25, 2024Dec 31, 2026phase 4 · NCT07243379
Bristol-Myers Squibbits history only30 open or runningphase 4since Nov 2, 1999Nov 2, 1999none ahead
Par Healthits history only30 open or runningphase 3since Mar 11, 2008Mar 11, 2008none ahead
Keenova Therapeuticsits history only20 open or runningphase 2since Mar 11, 2008Mar 11, 2008none ahead
Rottapharm Spainits history only20 open or runningphase 3since Jul 17, 2007Jul 17, 2007none ahead
TTY Biopharmits history only10 open or runningphase 2since Jul 25, 2016Jul 25, 2016none ahead

Also a collaborator on its studies: Quintiles, Covance, SFBC Anapharm and PRA Health Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Changchun GeneScience Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 25, 2024First study: phase 3 study in Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk FactorsFirst studyNCT06772428 · 96 planned · China
  2. Feb 11, 2025No phase study in Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line TreatmentNCT06830018 · 76 planned · China
  3. Apr 29, 20252 phase 3 studiesNCT06961201, NCT06961188
  4. Aug 25, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07150663 · 134 planned · China
  5. Nov 15, 2025Phase 4 study in Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaNCT07243379 · 495 planned · China
  6. Jan 4, 2026Phase 3 study in CachexiaNCT07356037 · 68 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 4 study in Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaNCT07243379
  2. Dec 31, 2026Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT06961201
  3. Jun 30, 2027Primary completion: phase 3 study in CachexiaNCT07356037
  4. Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07150663

TargetBeta

PGR →read by rule
“Progesterone receptor agonist”ChEMBL 37, by rule

Other programs on PGR

ProgramCompanyFurthest phaseStudies
LevonorgestrelruleBayerphase 456
drospirenoneruleestetraphase 420
Medroxyprogesterone AcetaterulePfizerphase 411
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Utrogestanrulecalla-lily-clinical-care-ltdphase 11

Studies

All 7 Changchun GeneScience Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07356037Cachexia · China3Not yet recruitingJun 30, 202768
NCT07243379Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia · China4RecruitingDec 31, 2026495
NCT07150663Carcinoma, Non-Small-Cell Lung · China3RecruitingJun 30, 2027134
NCT06961201Small Cell Lung Carcinoma · China3Not yet recruitingDec 31, 202694
NCT06961188Neoplasm Metastasis · China3Not yet recruitingJun 30, 2027174
NCT06830018Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line Treatment · China–RecruitingJan 202676
NCT06772428Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors · China3Not yet recruitingJun 30, 202796

How it is read

Names in the registry

  • “Nano-crystalline Megestrol Acetate Oral Suspension”, 5 entries
  • “Megestrol acetate concentrated suspension 125 mg/mL”, 5 entries
  • “Megestrol acetate”, 5 entries
  • “Nanocrystalline Megestrol Acetate”, 2 entries
  • “Megestrol acetate concentrated suspension 110 mg/mL”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.